Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 1
2011 1
2012 1
2014 1
2015 3
2016 2
2017 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort.
Wills AM, Li R, Pérez A, Ren X, Boyd J; NINDS NET-PD Investigators. Wills AM, et al. J Neurol. 2017 Aug;264(8):1746-1753. doi: 10.1007/s00415-017-8562-4. Epub 2017 Jul 15. J Neurol. 2017. PMID: 28712000 Free PMC article. Clinical Trial.
Weight loss is a common symptom of Parkinson's disease and is associated with impaired quality of life. Predictors of weight loss have not been studied in large clinical cohorts. We previously observed an association between change in body mass index and chan …
Weight loss is a common symptom of Parkinson's disease and is associated with impaired quality of life. Predictors of w …
Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort.
Bega D, Kim S, Zhang Y, Elm J, Schneider J, Hauser R, Fraser A, Simuni T. Bega D, et al. J Parkinsons Dis. 2015;5(4):773-82. doi: 10.3233/JPD-150668. J Parkinsons Dis. 2015. PMID: 26639661 Free article. Clinical Trial.
METHODS: Data from NINDS Exploratory Trials in PD Long-Term Study 1 (NET-PD LS1), a multicenter Phase 3 study of creatine in early treated PD, were analyzed. ...RESULTS: 765 of 1741 participants completed five-year assessments and were included. Older age at …
METHODS: Data from NINDS Exploratory Trials in PD Long-Term Study 1 (NET-PD LS1), a multicenter Phase 3 study of creatine …
Neuroprotective effects of creatine.
Beal MF. Beal MF. Amino Acids. 2011 May;40(5):1305-13. doi: 10.1007/s00726-011-0851-0. Epub 2011 Mar 30. Amino Acids. 2011. PMID: 21448659 Review.
Administration of creatine increases the brain levels of creatine and phosphocreatine. Due to its neuroprotective effects, creatine is now in clinical trials for the treatment of Parkinson's disease (PD) and HD. ...Creatine is now …
Administration of creatine increases the brain levels of creatine and phosphocreatine. Due to its neuroprotective effects, …
Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.
Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators. Parashos SA, et al. Arch Neurol. 2009 Sep;66(9):1099-104. doi: 10.1001/archneurol.2009.159. Epub 2009 Jul 13. Arch Neurol. 2009. PMID: 19597081 Free PMC article. Clinical Trial.
OBJECTIVE: To assess the predictive value of baseline measures of impairment, disability, and quality of life for the timing of initiation of symptomatic treatment in early Parkinson disease (PD). DESIGN: Inception cohort analysis. SETTING: Ambulatory population fro …
OBJECTIVE: To assess the predictive value of baseline measures of impairment, disability, and quality of life for the timing of initiation o …
Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators. Parashos SA, et al. JAMA Neurol. 2014 Jun;71(6):710-6. doi: 10.1001/jamaneurol.2014.391. JAMA Neurol. 2014. PMID: 24711047 Free PMC article. Clinical Trial.
IMPORTANCE: Optimizing assessments of rate of progression in Parkinson disease (PD) is important in designing clinical trials, especially of potential disease-modifying agents. ...CONCLUSIONS: AND RELEVANCE In early PD, the UPDRS Part II score and Part III sc …
IMPORTANCE: Optimizing assessments of rate of progression in Parkinson disease (PD) is important in designing clinical trials, …
Sex Differences in Clinical Features of Early, Treated Parkinson's Disease.
Augustine EF, Pérez A, Dhall R, Umeh CC, Videnovic A, Cambi F, Wills AM, Elm JJ, Zweig RM, Shulman LM, Nance MA, Bainbridge J, Suchowersky O. Augustine EF, et al. PLoS One. 2015 Jul 14;10(7):e0133002. doi: 10.1371/journal.pone.0133002. eCollection 2015. PLoS One. 2015. PMID: 26171861 Free PMC article. Clinical Trial.
INTRODUCTION: To improve our understanding of sex differences in the clinical characteristics of Parkinson's Disease, we sought to examine differences in the clinical features and disease severity of men and women with early treated Parkinson' …
INTRODUCTION: To improve our understanding of sex differences in the clinical characteristics of Parkinson's Disease, w …
Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.
Elm JJ; NINDS NET-PD Investigators. Elm JJ, et al. Mov Disord. 2012 Oct;27(12):1513-21. doi: 10.1002/mds.25175. Mov Disord. 2012. PMID: 23079770 Free PMC article. Clinical Trial.
Based on the preclinical data and the results of a phase II futility study, creatine was selected for an efficacy trial in Parkinson's disease (PD). We present the design rationale and a description of the study cohort at baseline. A randomized, multic …
Based on the preclinical data and the results of a phase II futility study, creatine was selected for an efficacy trial in Parkins …
A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results.
NINDS NET-PD Investigators. NINDS NET-PD Investigators. Clin Neuropharmacol. 2008 May-Jun;31(3):141-50. doi: 10.1097/WNF.0b013e3181342f32. Clin Neuropharmacol. 2008. PMID: 18520981 Free PMC article. Clinical Trial.
OBJECTIVE: To report an 18-month follow-up on creatine and minocycline futility study, the Neuroprotective Exploratory Trials in Parkinson Disease, Futility Study 1 (NET-PD FS-1). BACKGROUND: The NET-PD FS-1 futility study on cr …
OBJECTIVE: To report an 18-month follow-up on creatine and minocycline futility study, the Neuroprotective Exploratory Trials in P …
Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1.
Wills AM, Pérez A, Wang J, Su X, Morgan J, Rajan SS, Leehey MA, Pontone GM, Chou KL, Umeh C, Mari Z, Boyd J; NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators. Wills AM, et al. JAMA Neurol. 2016 Mar;73(3):321-8. doi: 10.1001/jamaneurol.2015.4265. JAMA Neurol. 2016. PMID: 26751506 Free PMC article.
IMPORTANCE: Greater body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) is associated with improved survival among persons with Huntington disease or amyotrophic lateral sclerosis. Weight loss is common among persons with Parkins …
IMPORTANCE: Greater body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) is associated with improved …
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
NINDS NET-PD Investigators. NINDS NET-PD Investigators. Neurology. 2006 Mar 14;66(5):664-71. doi: 10.1212/01.wnl.0000201252.57661.e1. Epub 2006 Feb 15. Neurology. 2006. PMID: 16481597 Clinical Trial.
BACKGROUND: Creatine and minocycline were prioritized for testing in Phase II clinical trials based on a systematic evaluation of potentially disease modifying compounds for Parkinson disease (PD). ...CONCLUSIONS: Both creatine and minocycline s …
BACKGROUND: Creatine and minocycline were prioritized for testing in Phase II clinical trials based on a systematic evaluation of pot …
12 results